Enveric Biosciences announced the company has agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin. The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea. Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENVB:
- Enveric Biosciences Unveils New Mental Health Compounds
- Enveric Biosciences Granted Extension to Avoid Nasdaq Delisting
- Enveric Biosciences initiated with a Buy at H.C. Wainwright
- Enveric Biosciences files to sell 2.24M shares of common stock for holders
- Enveric Biosciences sells 1.122M shares at $1.37 in private placement